Overview
1. Introduction
Rh immune globulin is a passive anti D immune globulin used to prevent RhD alloimmunization in a pregnant or postpartum client who is RhD negative and not already sensitized.
Rh immune globulin is a passive anti-D immune globulin used to prevent RhD alloimmunization in a pregnant or postpartum client who is RhD-negative and not already sensitized. At NP level, the focus is not only “give RhIg at 28 weeks.” The NP must know how to determine candidacy, interpret antibody results, order appropriate testing, manage sensitizing events, identify when standard dosing may be insufficient, and distinguish prevention from management of established alloimmunization. SOGC’s 2024 guideline addresses prevention of RhD alloimmunization across parental testing, routine antepartum and postpartum prophylaxis, and other clinical indications for prophylaxis. ACOG’s core recommendation remains that unsensitized RhD-negative pregnant patients should be offered anti-D immune globulin at 28 weeks, and postpartum RhIg should be given within 72 hours when the infant is RhD-positive.